ClinConnect ClinConnect Logo
Search / Trial NCT03387605

Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine

Launched by LOYOLA UNIVERSITY · Dec 22, 2017

Trial Information

Current as of June 13, 2025

Unknown status

Keywords

ClinConnect Summary

This study will explore the hypothesis that Ivabradine will decrease heart rate (HR) and improve hemodynamics in patients with advanced HF on inotropic treatment. This is a randomized, double blind, single center trial will include 40 consecutive patients admitted for Stage D HF/ CS who will require continuous infusion of Dobutamine and will develop ST (HR \>100 beats/min).

Eligible patients will be randomized (1:1) using blocked randomization with random block sizes of 2 or 4 to start Ivabradine versus placebo. The procedure of randomization to receive either Ivabradine or placebo twice d...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Provide written informed consent for the study
  • Have current diagnosis of Ischemic and/or non-ischemic cardiomyopathy
  • Left ventricular ejection fraction (LVEF) \< 30% by echo during the screening
  • Sinus rhythm with HR ≥100 bpm
  • Systolic blood pressure ≥ 90 mmHg assessed by cuff sphygmomanometer
  • CI \< 2.2 L/min/m2
  • Current symptom(s) of HF (New York Heart Association (NYHA) class IV) at Screening.
  • Absence of hypovolemia, defined as a central venous pressure ≥10 mmHg and pulmonary capillary occlusion pressure ≥15 mmHg before administration of Dobutamine
  • Exclusion Criteria:
  • Respiratory support with mechanical ventilation
  • Circulatory mechanical support
  • Atrial pacing with the presence of sick sinus syndrome or sino-atrial block
  • Second or third degree atrioventricular (AV) block,
  • Atrial fibrillation/flutter
  • Amiodarone treatment
  • Ventricular tachycardia
  • Acute coronary syndrome
  • Bilirubin \> 2.5
  • Alanine aminotransferase (ALT) \>60 IE/L,
  • Serum creatinine \>2.5 g/ml)
  • Fever and significant infection
  • Pregnancy
  • Anemia, Hgb \< 9.0
  • Patients required treated with severe cytochrome CYP3A4 inhibitors drugs Concomitant use of strong CYP3A4 inhibitors will be avoided during the study period

About Loyola University

Loyola University is a prestigious academic institution dedicated to advancing medical research and clinical innovation. As a sponsor of clinical trials, Loyola University leverages its extensive resources, expert faculty, and commitment to ethical research practices to explore new therapeutic interventions and improve patient outcomes. The university fosters a collaborative environment that brings together multidisciplinary teams to conduct rigorous studies across various fields of medicine, ensuring that the findings contribute to the broader healthcare community and enhance evidence-based practices. Through its dedication to scientific excellence and community health, Loyola University remains at the forefront of clinical research initiatives.

Locations

Maywood, Illinois, United States

Patients applied

0 patients applied

Trial Officials

Eugenia Raichlin, MD

Principal Investigator

Loyola University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials